Table 1

Demographic and clinical characteristics of the 21 patients with systemic sclerosisa

Characteristics

SSc patients (N = 21)


Mean age (±SD), yr

56.5 ± 12.1

Sex, n (%)

   Male

4 (19.1)

   Female

17 (80.9)

Disease subset, n (%)

   lSSc

13 (61.9)

   dSSc

8 (38.1)

Mean disease duration (±SD), yrb

7.7 ± 4.1

Autoantibody positivity, n (%)

   ANA

21 (100)

   Anti-Scl-70

7 (33.3)

   ACA

10 (47.6)

Digital ulcers, n (%)

12 (57.1)

Nailfold capillaroscopy pattern, n (%)

   Early

4 (19.0)

   Active

8 (38.1)

   Late

9 (42.9)

Mean skin score (±SD)

10.2 ± 6.3

ILD, n (%)c

11 (52.4)

CYC treatment, n (%)

13 (61.9)d


aACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl-70, anti-Scl-70 antibodies; CYC, cyclophosphamide; dSSc, diffuse cutaneous systemic sclerosis; ILD, interstitial lung disease; lSSc, limited cutaneous systemic sclerosis; SSc, systemic sclerosis. Except where indicated otherwise, values are the number (%) of participants. bDisease duration was calculated from the date of the first non-Raynaud's symptom of SSc. cDetermined by high-resolution computed tomography scan. dEight patients with lSSc and five patients with dSSc.

Villano et al. Arthritis Research & Therapy 2013 15:R90   doi:10.1186/ar4270

Open Data